Core Operational and Financial Risk Management Controls for Over-the-Counter Derivatives Activities of Registered Persons

適用於註冊人的衍生工具場外交易活動的核心運作和財務風險管理機制

March 1995
Hong Kong
INTRODUCTION

1. The Securities and Futures Commission has issued this Introduction and Parts I and II of the attached Guidelines, except for paragraphs 11 and 12, for use by registered persons engaged in over the counter ("OTC") derivatives activities. They are published under section 4(2) of the Securities and Futures Commission Ordinance and indicate the criteria which the Commission will apply in assessing whether those who are engaged in OTC derivatives activity are fit and proper persons to be engaged in such activity whilst registered with the Commission. These criteria are in addition to any other relevant fit and proper criteria issued by the Commission. Hong Kong actively participated in the formulation of the Guidelines by the International Organisation of Securities Commissions ("IOSCO") in July 1994 and fully supports the initiatives being taken by IOSCO to regulate OTC derivatives activities in the world markets. The Introduction and Guidelines are issued in pursuance of this active support.

2. The Commission notes that the general principles underlying Parts I and II of the IOSCO guidelines are applicable to many aspects of the activities which it supervises and that they may have already been absorbed into the risk management structure of firms whether or not they are currently engaged in derivatives activities. Nevertheless the Commission has formally adopted these Parts of the IOSCO guidelines as a statement of minimum best practice for registered persons in respect of their management control systems and procedures for OTC derivatives activities. It expects registered persons to adopt the statement for internal control purposes in order to satisfy the fit and proper criteria. When undertaking on-site inspections, the Commission would expect firms to demonstrate compliance with this introduction and Part I and II of the guidelines, except for paragraphs 11 and 12.

3. The Commission also accepts that the manner in which the statements are applied may vary as between firms and that this reflects the dynamic and evolving nature of the derivatives industry. It is conscious of the need to allow this flexibility to firms and is prepared to accept variants provided that any firm's risk management systems are no less stringent than those stated in the guidelines. It would expect such firms to fully document their systems and procedures and to be able to demonstrate that their own specific internal controls are at least as stringent as the worldwide approach contained in the IOSCO guidelines.
Summary of the IOSCO guidelines

4. The Commission expects registered firms to have regard to the following matters which are covered in detail in the IOSCO guidelines:

(a) Framework of Risk Management

There must be clearly stated risk management policies and procedures overseen by the board of directors or equivalent senior management body, well defined chains of responsibility and provision for accurate, informative and timely reports.

(b) Independent Market Risk Management

The firm must have an independent market risk management function to monitor the application of risk limit policies, to review and approve pricing models and valuation systems (including mark-to-market mechanisms).

(c) Independent Credit Risk Management

The firm must have an independent credit risk management function to set and monitor credit limits, and to review leverage, concentration and risk reduction arrangements.

(d) In-House Expertise and Resources

Firms should dedicate adequate resources to all aspects of risk management controls, including back office systems and accounting and supervision and ensure adequate training.

(e) Risk Reduction Techniques

Firms should as appropriate use risk reduction techniques such as master agreements, netting arrangements, collateralization of transactions and third party credit enhancements, including letters of credit and guarantees. Firms also should consider risk reduction techniques to address operations risk, including contingency planning.
(f) **Valuations and Exposures**

Firms should make accurate risk valuations daily, using an acceptable pricing methodology to mark-to-market and to identify concentrations. Potential exposures to credit and market risk should also be calculated using appropriate methodologies. Exposures may be aggregated provided netting arrangements are acceptable and enforceable.

(g) **Systems**

Firms' accounting, risk management and information systems should ensure adequate and timely documenting, processing, confirming, approving as appropriate, and reconciling of trades and valuation systems used by front and back offices; assessing of risk on a global (firm-wide) basis; accurate and timely reporting to management; and external reporting by management. Internal or external independent systems reviews should be used to verify that such systems are operating as designed.

(h) **Liquidity, Funding Arrangements and Financial Performance**

Firms need to monitor on a continuing basis financial performance, including profit and loss, funding requirements and sources and cash flows.
Operational and Financial Risk Management Control Mechanisms For Over-the-Counter Derivatives Activities of Regulated Securities Firms

Issued by The Technical Committee Of The International Organization of Securities Commissions ("IOSCO")

July, 1994
FOREWORD

In this paper, the Technical Committee of IOSCO sets out a framework of management control mechanisms for regulators of securities firms doing over-the-counter (OTC) derivatives business\(^1\). The purpose of this paper is to provide guidance to securities regulators as to those management control mechanisms which (as appropriate in the context of each regulator’s particular regulatory jurisdiction and approach) they should seek to promote or encourage for use by regulated securities intermediaries. The paper contains a flexible, non-exclusive approach to management controls intended to cooperatively reinforce regulators’ promotion of prudential practices while permitting those practices to continue to evolve.

This paper is being issued at the same time as a similar paper on management controls for derivatives being published by the Basle Committee on Banking Supervision. While the two papers differ in detail, the two Committees share the common objective of promoting sound risk management controls and the papers reflect that securities firms’ and banks’ derivatives activities give rise to similar risks and risk management concerns.

The paper confirms that both Committees attach great importance to prudential risk management on the part of financial institutions. The Committees expect to continue to consult as market and supervisory practices develop.

\(^1\) This paper was prepared by Working Party No. 3 of the Technical Committee of IOSCO. The members of the Working Party are set out in Appendix C.
PART I
BACKGROUND

OTC Derivatives and Risk

1. Derivatives are financial instruments whose values are derived from, and reflect changes in, the prices of the underlying products. They are designed to facilitate the transfer and isolation of risk and may be used for both risk transference and investment purposes. As such, they play a valuable role for users of the marketplace. However, they also may increase risk. In view of the rapid growth of OTC derivatives business, numerous international groups and regulatory agencies have studied the risks arising from over-the-counter (“OTC”) derivatives trading\(^2\). These risks include:

- **Credit risk** - the risk that a counterparty will fail to perform an obligation owed to the firm;
- **Market risk** - the risk that movements in prices or values will result in loss for the firm;
- **Liquidity risk** - the risk that a lack of counterparties will leave a firm unable to liquidate or offset a position (or unable to do so at or near the previous market price);
- **Settlement risk** - the risk that a firm will not receive funds or instruments from its counterparty at the expected time;
- **Operations risk** - the risk that a firm will suffer loss as a result of human error or deficiencies in systems or controls;
- **Legal risk** - the risk that a firm will suffer loss as a result of contracts being unenforceable or inadequately documented.

2. Such risks are not unique to OTC derivatives transactions, but are of special concern due to the volume, scope, and variety of OTC transactions, the degree of interrelatedness of participants, the opacity and uncertain liquidity of OTC “markets”, and the complexity of and potential leverage in such instruments. Although it is possible to unbundle the risks of complex instruments into simpler elements, evolving portfolio and pricing technologies are permitting the engineering of increasingly complex financial instruments which have risk profiles that are more difficult to analyze than simpler, one-dimensional financial

---

\(^2\) See Appendix A to this paper for a list of studies of OTC derivatives trading and related documents generated by international groups and regulatory agencies.
products. The financial risks of such complex instruments must be carefully assessed as a
weakness at one market participant can have ramifications elsewhere in the system.

Importance of Management Controls

3. It is now generally acknowledged by financial services regulators, financial services
providers and corporate users alike, that a key component of a robust framework for the
management of the risks attaching to OTC derivatives business is a strong structure of risk
management controls within firms active in this business.

4. The Technical Committee recognizes that market forces can provide significant incentives
for firms to develop effective operational and financial risk control mechanisms. In order to
safeguard their own position, firms may well terminate or restrict activities with market
participants as to which there may be doubts as to the adequacy of their management
controls. Moreover, a firm's own commercial interests are likely to ensure that it checks that
a counterparty (a) has the power to enter into a proposed transaction, (b) is represented by
an officer with actual or ostensible authority, (c) is creditworthy, and (d) has access to
appropriate payment systems.

5. Nonetheless, market forces may also lead firms to ignore or under-estimate risks, including
those arising from known control deficiencies, where commercial pressures create an
impetus towards entering into certain transactions, including innovative transactions.
Furthermore, even the beneficial effects of market forces on controls are achieved by an
evolutionary process and so may not address regulatory concerns sufficiently quickly or
generally. The Technical Committee believes that the achievement of adequate
operational and financial risk control mechanisms cannot be left solely to the influence of
market forces.

6. The Technical Committee accordingly is publishing this paper by way of guidance to
securities regulators (including self-regulators), intermediaries, and examiners of
intermediaries as to the kinds of controls and operational practices that need to be
considered in the development of a strong risk management structure. Although not
directed at end-users, this guidance will nonetheless provide a reference point concerning
procedures and controls that also may be relevant to effective risk management by
end-users. Given the ease with which derivatives cross borders, and the degree to which
OTC derivatives business is transnational, the Technical Committee considers that the
articulation of this guidance on a transnational basis is particularly appropriate.

7. In developing this guidance in the context of OTC derivatives business, the Technical
Committee recognizes that much of the guidance is likely to be of general application to the
effective management by a firm of all of its risks. As a consequence, risk management
control mechanisms for OTC derivatives should be integrated within a firm's overall risk
management framework.
8. The Technical Committee also recognizes that strong management controls are only one element of the management of financial exposures. In particular, they are not a substitute for adequate capital.

9. Part II of this paper identifies a number of specific management control mechanisms. These are non-exclusive. The control structure that should be established, and the practices that should apply, in the case of any particular institution must be appropriate to that institution relative to the scale, the risk profile and the complexity of its OTC derivatives activities. Accordingly, additional or different controls may be of importance in particular situations. The mechanisms are intended to form a framework within which regulators, self-regulators and firms may design, subject to national consultation or otherwise, more specific risk management practices and procedures as necessary and appropriate to address regulatory or managerial needs in a specific context.

10. Therefore, this document takes the form of guidance rather than normative standards. This reflects the view that:

   • the structures, size and resources, and the business volume, diversity and complexity, of firms active in OTC derivatives business differ sufficiently that generically specified controls would not be adequately tailored to the environment in which they are likely to operate;

   • a prescriptive approach may inadvertently not address significant risk at some firms or cause other firms to waste resources on operating controls which they do not need;

   • a prescriptive approach may inadvertently hinder the market development of sophisticated control practices, which are constantly evolving;

   • a prescriptive approach may not take adequate account of juridical differences or differences in the allocation of regulatory authority among national regulators;

   • a non-prescriptive approach enables regulators to encourage individualized solutions to the desired objectives of management control mechanisms and to balance customer and systemic protection with the need to avoid impeding commercial activity; and

   • a non-prescriptive approach, which establishes internationally agreed operational and financial risk management control objectives, may, if widely and publicly adopted by regulators and prominent firms, raise the consciousness of and otherwise influence non-regulated intermediaries and other market participants, as well as unregulated commercial end-users.
11. Although this paper takes the form of guidance, the Technical Committee attaches great importance to the achievement in practice of sound risk management controls. Individual regulators, therefore, need to explore the various means whereby they can promote high standards and the ways in which they can be given confidence that such high standards are in place and are being applied in practice.

12. The Technical Committee recognizes that there are a number of different possible regulatory approaches to the achievement by firms of satisfactory operational and financial control mechanisms. A number of options are briefly discussed in Appendix B. Often, it will be appropriate to use a combination of approaches. Given variations in national regulatory styles and responsibilities, the Technical Committee does not envisage a common regulatory approach to achieving the objectives of the mechanisms. However, the Technical Committee, collectively, does believe that the mechanisms are important elements of an appropriate risk management framework.

13. In developing this guidance, the Technical Committee has been working in parallel with the Basle Committee on Banking Supervision, which also has been developing risk management guidelines for derivatives. The two Committees, while considering it appropriate to examine their own needs in the first instance, have kept informal contact on their respective projects. There are some differences of perspective deriving from differences in the overall supervisory context of banks and non-banks, and some traditional differences of supervisory style and technique. However, it is apparent that both bank and securities supervisors believe that strong management controls are an essential element of managing OTC derivatives risk.
PART II
RISK MANAGEMENT CONTROL MECHANISMS

1. Framework of Risk Management

The framework of risk management policies and procedures and management controls overseen by the board of directors or equivalent management body of the firm should specifically cover derivatives activity, clearly establish responsibility for its implementation, and provide for accurate, informative and timely reporting to management. This framework should be communicated to all concerned and should be reviewed as business and market circumstances change.

The firm's board of directors or other equivalent body should establish and communicate risk management policies and procedures for OTC derivatives activities that are integrated with the firm's overall management policies. Such policies and procedures should address the measurement of market risk and credit risk including aggregate exposures against risk tolerance objectives (position limits or capital at risk); acceptability criteria for counterparties, strategies and products (hedging, covered writing, risk management, position taking and related legal risks); risk monitoring procedures and exception reporting criteria; personnel policies (including expertise, training and compensation policies); the separation of trading and risk management functions; and the establishment of management controls and checks over accounts, traders, operational staff and systems.

The framework should provide for two-way communication between the board and persons responsible for implementing board policies.

Delineation of derivatives authority should be without prejudice to ultimate board supervisory responsibility.

2. Independent Market Risk Management

Management controls should provide for independent market risk management at the firm to develop and monitor the application of risk limit policies, to review and approve pricing models and valuation systems (including mark-to-market mechanisms) for use by front and back office staff, to re-assess such systems
from time to time as appropriate, to monitor for significant variances in the volatilities, and to carry out stress simulations.

Controls should address stress scenarios, confidence levels, credit assumptions and market risk measurement methodologies, separation of back office, accounting and compliance functions from trading, risk policies and integration of accounting systems. Stress tests should test the consequences of severe price moves and changes in market behavior, including changes in correlations and other risk assumptions.

3. **Independent Credit Risk Management**

Management controls should provide for independent credit risk management at the firm to consider credit exposure measurement standards, set and monitor credit limits, and to review leverage, concentration and risk reduction arrangements.

Appetite for risk, quality of credits, level of concentration, reliance on credit enhancements, measurement methodologies and separation of sales supervision from exposure supervision should be subject to controls. Controls also should address the risk of failure to deliver or of termination provisions, as appropriate.

4. **In-House Expertise and Resources**

In view of the speed of evolution and complexity of derivatives products, firms should devote adequate resources to all aspects of risk management controls, including back office systems and accounting and supervision. Firms also should make every effort to ensure that knowledge at all levels of the firm, and of traders and risk managers is adequate in terms of market developments for the appropriate assessment and management of risks.

5. **Risk Reduction Techniques**

Firms should as appropriate use risk reduction techniques such as master agreements, netting arrangements, collateralization of transactions and third party credit enhancements, including letters of credit and guarantees. Firms also should consider risk reduction techniques to address operations risk, including contingency planning.

Controls should address credit enhancements in terms of exposure and explore the use of master agreements to reduce documentation
risk and to increase the potential to assign and/or otherwise unwind transactions. Legal capacity of counterparties to transact and legality of netting arrangements should be evaluated.

6. Valuations and Exposures

Firms on both an entity and a group basis should have the capability to make accurate risk valuations daily, using an acceptable pricing methodology to mark-to-market and to identify concentrations. Potential exposures to credit and market risk should also be calculated using appropriate methodologies. Exposures may be aggregated provided netting arrangements are acceptable and enforceable.

Arrangements should be made to value dynamic portfolios sufficiently frequently to address exposures taking into account legal netting arrangements. Outputs of simulations should be tested against actual results and adjusted accordingly.

7. Systems

Firms' accounting, risk management and information systems should ensure adequate and timely documenting, processing, confirming, approving as appropriate, and reconciling of trades and valuation systems used by front and back offices; assessing of risk on a global (firm-wide) basis; accurate and timely reporting to management; and external reporting by management. Internal or external independent systems reviews should be used to verify that such systems are operating as designed.

The complexity and dynamic nature of derivatives trading activity and portfolios require that accurate and timely information is always available. Systems must be kept constantly under review to be certain that they permit tracking and reporting financial performance and effectuating management policies. Significant deficiencies in the design or operation of the systems that could adversely affect the entity's ability to record, process, summarize, and report financial data should be reported upon. This is not intended to define the scope of external financial audits.

8. Liquidity, Funding Arrangements and Financial Performance

Firms need to monitor on a continuing basis financial performance, including profit and loss, funding requirements and sources and cash flows.
Risk management personnel need to take account of revenues and the adequacy of funding arrangements in designing and implementing risk management strategies. Liquidity planning should attempt to anticipate changes in cash flow or funding requirements and should accommodate the possible need to rebalance portfolios, augment collateral, and permit the management of defaults.
Appendix A

OTC DERIVATIVES STUDIES AND RELATED DOCUMENTS

Risk Management Guidelines for Derivatives, Basle Committee on Bank Supervision (July, 1994).

Detailed Questions About Derivatives, American Institute of Certified Public Accountants (June 15, 1994).


OTC Derivatives Oversight, Statement of the Securities and Exchange Commission, the Commodity Futures Trading Commission, and the Securities and Investments Board (March 15, 1994).


Memo to the Officer in Charge of Supervision at each Federal Reserve Bank, re Examining Risk Management and Internal Controls for Trading Activities of Banking Organizations, Division of Banking Supervision and Regulation, Board of Governors of the Federal Reserve System (December 20, 1993).


Appendix B

THE ROLE OF REGULATORS

Individual national regulators will need to determine how best to cause firms subject to their regulatory jurisdiction to develop control policies and procedures to meet the performance objectives set forth in this paper. Regulators may wish to consult further with appropriate industry groups for this purpose. With respect to regulated entities, a number of approaches to identifying appropriate management control mechanisms and ensuring that they are effectuated in practice are identified and briefly discussed below.

A. Adopt performance or design standards.

Where they have appropriate jurisdiction, regulators could promulgate regulations setting performance or design standards. Regulators could mandate that firms engaging in OTC business have in place a system of operational and financial risk management controls which addresses the issues and meets the objectives specified in Part II above. Regulators could require report by self-audit or third-party audit of material inadequacies or deficiencies in such controls on a periodic basis (e.g., a condition that could inhibit the completion of transactions or result in a failure of an accounting or risk-management system). See E. below.

The appropriate level of detail required to be specified in a system is a matter for discussion. Regardless of the specificity of the policies adopted, the need for management to articulate its system and policies should have a beneficial effect. In particular, such a review should cause management to focus on potential risks and benefits of derivatives as a component of financial and funding activities in general.

Regulators could also consider devising new regulations specifically tailored to OTC derivatives activity. For example, regulators could enact rules expressly requiring regulated firms to supervise their OTC derivatives traders and risk managers and to obtain and maintain timely specified documentation and records of derivatives transactions (e.g., similar to underwriting logs, deal sheets, confirmations, etc.) or to follow other specific risk reduction methodologies (e.g., use master agreements, and document credit analyses).

B. Interpret existing rules to subsume management control requirements for OTC business.

Many regulators currently measure compliance with certain supervisory or other prudential requirements by evaluating management control mechanisms of firms. For example, many
jurisdictions interpret their supervisory requirements for regulated entities to apply to accounts, systems, and personnel and to reach up the chain of command to the person with the ultimate authority to hire or fire. Under this reading, certain members of the board of directors may be cited for supervisory failures relative to firm operational controls. Effective management controls generally are considered essential to meeting such supervision requirements.

Other types of requirements could also be met through the implementation of management controls. For example, certain fiduciary requirements in some jurisdictions preclude an intermediary from acting in conflict with the interests of its customers. Further, most regulators impose various recordkeeping requirements on regulatees and/or require minimum capital levels and reporting of shortfalls immediately. This necessitates systems to produce the desired reports. These rules are not particularized to OTC risks and, in some cases, would have to be extended by interpretation to cover such risks.

Some jurisdictions also regard corporate board members and certain types of end-user management (e.g., pension funds) as fiduciaries and impose duties of care and financial responsibility or prudence that may need to be addressed through adequate management and operational controls.

C. Collect information on risks and risk management controls and policies.

Rules also could be adopted which authorize regulators to collect specified information on risks related to OTC derivatives activity undertaken in affiliates of regulated entities and on risks management policies of the regulated firms. Such rules have the beneficial effect of requiring risk analyses to be undertaken within firms by officers responsible for financial reports.

In jurisdictions which require consolidated supervision, guidance could be issued as to how to achieve group controls.

D. Require assessment of counterparties.

Regulators could mandate that regulated intermediaries inquire before entering into transactions with potential counterparties as to certain specified management controls (e.g. marking-to-market and documentation).

Regulators also could consider making inquiries into the existence of management controls (or representations as to their existence) relevant to so-called "suitability", "know your customer", "authority" or "access" determinations made by persons marketing OTC derivatives.
E. Require management assessments and regulatory examinations or auditor’s reports on controls - either by internal independent audit staffs or third-party auditors.

Regulators could periodically examine firms’ practices and comment on controls in place or could issue rules or guidance compliance with which is established through routine audits conducted by regulators or relevant self-regulating organizations (“SROs”).

Regulators also could require management of regulated firms periodically to assess and to document their implementation of the firm’s risk management policies, and require the submission of reports on those policies (by independent internal audit staffs, or independent third parties) to regulators.

The discipline of self-assessment and independent auditing and reporting to regulators could be expected to heighten the attention of all levels of management and the board of directors as to the importance of such controls.

A number of models for reporting to regulators by auditors and reporting accountants already exist. In addition to routine reporting arising from audits or specific regulatory assignments, regulators may wish to consider requiring *ad hoc* reporting by auditors of matters which become known to them in the course of their work3.

F. Require Self-Regulatory Organization oversight by reference to industry standards.

In addition to (or as an alternative to) rulemaking aimed directly at market participants, regulators may consider requiring industry SROs to adopt rules directing their members to employ specific management control mechanisms.

Regulators also may wish to encourage SROs to implement procedures for SRO or other third-party review of individual firms’ management controls. Separately, SROs may seek to develop innovative means of ensuring their members meet management control objectives.

G. Require pre-clearance of systems and controls as part of fitness determinations.

Controls could be reviewed as part of fitness determinations and qualifications to engage in specific types of business.

---

3 See e.g. E.C. Post-BCCI Directive; GAAS Guide, at 7.37, quoting Statement of Auditing Standards - 60 (Communication of Internal Control Structure Related Matters Noted in an Audit); and Bulletin B., Mexican GAAS.
H. Limit OTC dealer activity to regulated intermediaries.

In order to encourage appropriate use of management policies related to market, credit and other risks, regulators could require OTC dealing activity to be undertaken solely by regulated intermediaries, those causing existing supervisory rules to pertain to all derivatives dealers.

This approach is complicated by the fact that in most jurisdictions the intermediaries engaged in OTC business are subject to various regulatory regimes. For example, such activities could be conducted in a bank, a securities firm, a commodities intermediary firm, a pension fund or collective investment vehicle, or by a merchant or trader. To the extent activity is undertaken in an entity engaging in "dealing" (that is, "two-way" market making) activities that are not regulated two questions arise: which regulator and which institutional model should be followed. This also raises questions about regulatory convergence between differently regulated institutions. Some jurisdictions consider it unlikely that this is a viable alternative.

I. Nonregulated Market Participants.

While regulators cannot impose management control requirements directly over nonregulated entities, regulators may be able to influence the acceptance of best practice.

Nonregulated firms do have significant economic incentives adequately to supervise employees and effectively to manage their derivatives risk. Regulators nevertheless could promote best practice by all potential counterparties by encouraging regulated intermediaries to use contractual or documentation practices that address certain of their customers’ management control mechanisms such as marking-to-market or specified documentation.
### IOSCO WORKING PARTY NO. 3

#### PARTICIPANTS

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Peter Clarke</td>
<td>Australian Securities Commission</td>
</tr>
<tr>
<td>Canada</td>
<td>Rozanne Reszel</td>
<td>Canadian Investor Protection Fund</td>
</tr>
<tr>
<td>France</td>
<td>Didier Davydoфф</td>
<td>Commission des Opérations de Bourse</td>
</tr>
<tr>
<td></td>
<td>Francois Champernaud</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emmanuel Carraere</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>Dr Joachim Henke</td>
<td>Bundesministerium der Finanzen</td>
</tr>
<tr>
<td></td>
<td>Werner Gehring</td>
<td>Deutsche Bundesbank</td>
</tr>
<tr>
<td></td>
<td>Dr Uwe Neumann</td>
<td>Bundesaufsichtsamt fur das Kreditwesen</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>Siva Singham</td>
<td>Securities and Futures Commission</td>
</tr>
<tr>
<td>Italy</td>
<td>Dr M Antonietta Scopelliti</td>
<td>Commission Nazionale Per la</td>
</tr>
<tr>
<td></td>
<td>Carlo Biancheri</td>
<td>Società e la Borsa</td>
</tr>
<tr>
<td>Japan</td>
<td>Toru Shikibu</td>
<td>Ministry of Finance</td>
</tr>
<tr>
<td></td>
<td>Kenta Ichikawa</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Miguel Cano</td>
<td>Comision Nacional de Valores</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Cor-Jan Dasselaar</td>
<td>Securities Board of the Netherlands</td>
</tr>
<tr>
<td>Spain</td>
<td>Ester Martinez Cuesta</td>
<td>Comision Nacional del</td>
</tr>
<tr>
<td></td>
<td>R Martinez-Pardo del Valle</td>
<td>Mercado de Valores</td>
</tr>
<tr>
<td>Sweden</td>
<td>Lennart Torstensson</td>
<td>Financial Supervisory Authority</td>
</tr>
<tr>
<td></td>
<td>Hans Boberg</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>Daniel Zuberbühler</td>
<td>Swiss Federal Banking Commission</td>
</tr>
<tr>
<td></td>
<td>Urs Brügger</td>
<td>Swiss Admission Board</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Martin Vile, Chairman</td>
<td>Securities and Investments Board</td>
</tr>
<tr>
<td></td>
<td>Jane Coakley</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter Andrews</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tony Smith</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>Michael Macchiaroli</td>
<td>Securities and Exchange Commission</td>
</tr>
<tr>
<td></td>
<td>Harry Melamed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrea Corcoran</td>
<td>Commodity Futures Trading Commission</td>
</tr>
<tr>
<td></td>
<td>Jane Kang</td>
<td></td>
</tr>
</tbody>
</table>